Membranous nephropathy (MN) is the leading cause of nephrotic syndrome in nondiabetic adults worldwide, frequently leading to end-stage kidney disease (ESKD). Several discoveries in recent decades, including the emergence of B-cell depleting agents and the recognition of autoantibodies targeting podocyte antigens, revolutionized the understanding of MN in the native kidney. The impact of these discoveries in posttransplant recurrent MN remains to be determined. This article explores these questions through a joint effort involving 194 patients from 16 transplant centers spanning three continents.